Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | F10 | P00742 | 9/20 | 0.34 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.34 |
| ▸ | PLG | P00747 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23762242 | 0.90 | NR1H2 (0.43) | HRH3F10PORCNABCB1 | |
| SCHEMBL29836508 | 0.90 | NR1H2 (0.43) | HRH3F10PORCNABCB1 | |
| SCHEMBL22772343 | 0.85 | HRH3 (0.35) | HRH3F10PORCNPLGPRSS1 | |
| SCHEMBL22772329 | 0.85 | HRH3 (0.35) | HRH3F10PORCNPLGPRSS1 | |
| SCHEMBL22772328 | 0.83 | S1PR1 (0.37) | HRH3ABCB1KMT2A | |
| SCHEMBL23751241 | 0.83 | F10 (0.36) | HRH3F10PORCNPLGPRSS1 | |
| SCHEMBL23751145 | 0.83 | HRH3 (0.34) | HRH3F10PORCNPLGPRSS1 | |
| SCHEMBL23751254 | 0.83 | F10 (0.37) | HRH3F10PORCNPLGPRSS1 | |
| SCHEMBL23751117 | 0.82 | HRH3 (0.35) | HRH3F10PORCNPLGPRSS1 | |
| SCHEMBL23751164 | 0.82 | HRH3 (0.33) | HRH3F10PORCNPLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | HRH3 550/4885F10 3027/4885PORCN 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.